Portage Biotech Files 6-K, Incorporates into S-8
Ticker: ATON · Form: 6-K · Filed: Dec 17, 2024 · CIK: 1095435
| Field | Detail |
|---|---|
| Company | Portage Biotech INC. (ATON) |
| Form Type | 6-K |
| Filed Date | Dec 17, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, registration, foreign-private-issuer
Related Tickers: PTGE
TL;DR
Portage Biotech (PTGE) filed a 6-K, linking it to their S-8 registration. Keep an eye on potential stock dilution.
AI Summary
Portage Biotech Inc. filed a Form 6-K on December 17, 2024, reporting for the month of December 2024. The company is incorporated in the British Virgin Islands and its principal executive office is located in Tortola. This filing is incorporated by reference into its Form S-8 registration statement (File No. 333-275842).
Why It Matters
This filing indicates ongoing reporting requirements and potential future stock issuances or grants under the company's S-8 registration statement.
Risk Assessment
Risk Level: low — A Form 6-K is a routine filing for foreign private issuers and typically contains limited new material information.
Key Numbers
- 001-40086 — SEC File Number (Identifies the company's filing history with the SEC)
Key Players & Entities
- Portage Biotech Inc. (company) — Filer of the report
- 333-275842 (registration_statement) — Form S-8 file number
- December 17, 2024 (date) — Filing date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the company may be required to disclose or make public in its home country.
What is Form S-8 used for?
Form S-8 is used by companies to register securities to be offered to employees under employee stock option or other benefit plans.
What does it mean for this 6-K to be incorporated by reference into the Form S-8?
It means the information contained in this 6-K filing is considered part of the S-8 registration statement, potentially relating to the securities being registered for employee benefit plans.
Where is Portage Biotech Inc. incorporated and headquartered?
Portage Biotech Inc. is incorporated in the British Virgin Islands, with its principal executive office located in Tortola.
What is the SIC code for Portage Biotech Inc.?
The Standard Industrial Classification (SIC) code for Portage Biotech Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 312 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2024-12-17 07:05:05
Filing Documents
- f6k_121724.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 6KB
- 0001171843-24-006976.txt ( ) — 13KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-40086 PORTAGE BIOTECH INC. (Translation of registrant's name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] INCORPORATION BY REFERENCE This report on Form 6-K (including any exhibits attached hereto) shall be deemed to be incorporated by reference into the registration statement on Form S-8 (File No. 333-275842) of Portage Biotech Inc. (including any prospectuses forming a part of such registration statement) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. On December 17, 2024, Portage Biotech Inc. (the "Company") issued a press release announcing that it entered into a Letter of Intent (the "LOI") with Immunova, LLC, ("Immunova") a private Connecticut-based biotechnology company. Under the terms of the LOI, the Company and Immunova have agreed to negotiate a definitive option agreement for Immunova or an affiliate to acquire the entire share capital of iOx Therapeutics, Ltd, a wholly owned subsidiary of the Company. A copy of the press release is filed herewith as Exhibit 99.1. Exhibits Exhibit Number Description 99.1 Press Release dated December 17, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: December 17, 2024 PORTAGE BIOTECH INC. By: /s/ Andrea Park Andrea Park Chief Financial Officer